Semper Paratus shareholders approve extension to Sep 2024; $9.7M redeemed

Tevogen Bio Holdings Inc.

Shareholders approved extension of deadline to September 15, 2024 via one 3-month and six 1-month extensions.
880,873 Class A shares redeemed at ~$11.02/share for aggregate ~$9.7 million.
Trust account balance after redemptions and $67,500 payment is ~$16.5 million.
First extension to March 15, 2024 triggered by $67,500 deposit into trust.
Amendment to charter filed with Cayman Registrar to allow the extensions.

item 3.03 item 5.03 item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Tevogen Bio Holdings Inc.: Adopted and filed an amended charter to extend the deadline for an initial business combination to September 15, 2024, with a series of extension mechanisms and required deposits into the trust account (effective 2023-12-19).

Change: charter amendment
Effective: 2023-12-19

Exact text from the filing

At the Extraordinary General Meeting, the Shareholders approved the Extension Amendment Proposal for the Company to adopt and file the Amended Charter, which the Company promptly filed following the Shareholders’ approval.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Tevogen Bio Holdings Inc. shareholders approved Extension Amendment Proposal.

Outcome: passed

Exact text from the filing

The Shareholders approved the Extension Amendment Proposal. The following is a tabulation of the voting results: Ordinary Shares: Votes For Votes Against Abstentions Broker Non-Votes 14,359,632 5,967 0 N/A

View on SEC.gov

25 governance changes filed in the last 30 days. Browse all governance changes →

Tevogen Bio Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-045459

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.